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Abstract
Background: Prognostic index for survival estimation by clinical-demographic variables were previously proposed
in chronic lymphocytic leukemia (CLL) patients. Our objective was to test in a large retrospective cohort of CLL
patients the prognostic power of biological and clinical-demographic variable in a comprehensive multivariate
model. A new prognostic index was proposed.
Methods: Overall survival and time to treatment in 620 untreated CLL patients were analyzed retrospectively to
evaluate the multivariate independence and predictive power of mutational status of immunoglobulin heavy chain
variable gene segments (IGHV), high-risk chromosomal aberration such as 17p or 11q deletions, CD38 and ZAP-70
expression, age, gender, Binet stage, b2-microglobulin levels, absolute lymphocyte count and number of lymph
node regions.
Results: IGHV mutational status and 17p deletion were the sole biological variables with independent prognostic
relevance in a multivariate model for overall survival, which included easily measurable clinical parameters (Binet
staging, b2-microglobulin levels) and demographics (age and gender). Analysis of time to treatment in Binet A
patients below 70 years of age showed that IGHV was the most important predictor. A novel 6-variable clinical-
biological prognostic index was developed and internally validated, which assigned 3 points for Binet C stage, 2
points/each for Binet B stage and for age > 65 years, 1 point/each for male gender, high b2-microglobulin levels,
presence of an unmutated IGHV gene status or 17p deletion. Patients were classified at low-risk (score = 0-1; 21%),
intermediate-risk (score 2-5; 63% of cases), high-risk (score 6-9; 16% of cases). Projected 5-year overall survival was
98%, 90% and 58% in low-, intermediate- and high-risk groups, respectively. A nomogram for individual patient
survival estimation was also proposed.
Conclusions: Data indicate that IGHV mutational status and 17p deletion may be integrated with clinical-
demographic variables in new prognostic tools to estimate overall survival.
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Background
According to the updated National Cancer Institute-
Working Group (NCI-WG) guidelines, indication for
treatment of chronic lymphocytic leukemia (CLL) still
depends on clinical stage and disease activity [1]. In this
context, measurements of biological prognostic markers,
namely CD38, ZAP-70, mutational status of immunoglo-
bulin heavy chain variable gene segments (IGHV), are
judged as mandatory in the context of clinical trials, but
not in general practice, since they fail to influence thera-
peutic decisions [1]. The only exception is represented by
analyses of chromosomal aberrations by interphase fluor-
escence in-situ hybridization (FISH), given the presence
of high-risk cytogenetic lesions (del11q and del17p),
which may predict resistance to chemotherapy-based
treatments [2]. Wierda et al. [3] proposed to combine a
set of clinical risk factors, i.e age, gender, Rai staging,
absolute lymphocyte count (ALC) and number of
involved lymph node regions (LNR), with an inexpensive
and widely available serum marker such as beta2-micro-
globulin (b2 M) to develop a prognostic index (PI) strati-
fying patients in three risk groups with different expected
median survival, and a nomogram, estimating individual
patient survivals. This model was subsequently validated
in independent patients series also using time to first
treatment as end-point [4-8]. A reduction of this model
from six to four variables, i.e. age, gender, b2 M levels
and Binet staging, was also shown to predict survival
with equal or even better performance [8]. The object of
the present study was to provide evidence that prognostic
models for overall survival based on clinical variables
[4-8] could be improved by information on biological
risk factors. By retrospectively analyzing a multicentre
CLL population of over 600 untreated patients the most
significant and independent biological and clinical prog-
nosticators were integrated in a new clinical-biological
prognostic index for group stratification and in a novel
nomogram for estimating individual survival.
Methods
Patient population
Between 1996 and 2008 a cohort of 620 CLL patients was
collected in the context of a larger multicenter patient
dataset (n = 1037), previously utilized to propose a modi-
fied prognostic model and nomogram [8], according to
the availability of the following biological prognosticators:
IGHV mutational status, chromosomal abnormalities, as
detected by interphase FISH, and flow cytometric expres-
sion of CD38 and ZAP-70. Moreover, since most of the
diagnoses of the original patient set were made before
the publication of the revised NCI-WG guidelines [1], all
cases of previously defined CLL that could be re-classi-
fied as monoclonal B cell lymphocytosis (MBL) were
removed accordingly. The percentage of recruited cases
in the different centers was: 30% at Roma Catholic Uni-
versity, 25% at Novara, 15% at Roma Tor Vergata, 8% at
Siena, 6% at Milano, 4% each in the other 4 centers. Cut-
points for LNR were as previously reported [3]. Continu-
ous variables age and b2 M levels were categorized using
cut-points at 65 years for age and at the upper limit of
normal (ULN) for b2 M, as deduced by the analysis of
martingale residuals plots [9]; ALC was categorized at
the median, since the martingale residual plots did not
show any suitable cut-point.
Biological prognosticators
Evaluation of biological prognosticators was centralized in
few reference laboratories, utilizing previously validated
common procedures; in detail, 5 centers performed IGVH
mutational analysis, 6 centers performed cytogenetics and
flow cytometry. IGHV mutational status was performed as
previously reported [10]. Cytogenetic abnormalities invol-
ving chromosomes 11 (del11q22; hereafter del11), 12 (tris-
omy 12), 13 (13q14.3) and 17 (del17p13; hereafter del17)
were investigated by interphase FISH, as reported [11].
Results of FISH analyses were classified as unfavourable
when high-risk genomic aberrations (del17p and or del
11q) were present [12-14]. ZAP-70 measurements were
determined by flow cytometry, utilizing the 20% of positive
CLL cells as cut-off to discriminate between ZAP-70 posi-
tive and negative cases [15-18]. CD38 measurements were
performed as reported [19], using a threshold at 30%
expression to define positive cases. All the variables were
measured at or within one year from diagnosis and always
before treatment on either fresh or frozen samples. Data
were used upon informed consent from patients and
approval by Institutional Review Boards (Centro di Riferi-
mento Oncologico, Aviano; Catholic University of the
Sacred Heart, Rome), and in accordance with the Declara-
tion of Helsinki.
Statistical methods
All analyses were performed in R, an open source statisti-
cal package (http://www.r-project.org/). Median follow-up
was computed using the reverse censoring method. The
primary end points were overall survival (OS) and time-
to-first-treatment (TTT), defined as described [1,20,21].
OS was estimated using Kaplan-Meier plots and compared
between groups by log-rank test. Univariate and multivari-
ate Cox models were used to verify independent prognos-
tic power of each parameter. Model minimization was
performed by stepwise backward elimination. A p value
< 0.05 was considered to be statistically significant. Depar-
ture from proportionality in hazard was tested in all Cox
models. The predictive accuracy of various Cox models
was evaluated by calculating the concordance index
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(c-index), which is a probability of concordance between
predicted and observed survival, equal to the area under
the receiver operating characteristics curve for censored
data [22]. A c-index of 0.5 indicates that outcomes are
completely random, whereas a c-index of 1 indicates that
the model is a perfect predictor. Prediction error was cal-
culated as 1-c-index. U-statistics was applied to test the
significance between different c-index values [22]. Nomo-
gram was developed and calibrated following published
methods [22]. Final risk group scoring was developed in
four step: 1. selection of independent predictive variables;
2. fitting of a Cox model with selected variables; 3. score
assignments based on regression coefficients; 4. identifica-
tion of best cut-point to split the score in 3 risk groups by
recursive partitioning [23]. Internal validation for step 1.
and 2. was performed with bootstrap .632+ method
[24,25] with B = 620 bootstrap samples and (step 2) with
cross-validation [26]. Variables selected with a frequency
greater than 50% were entered in the final model. Risk
score categorical model obtained by recursive partitioning
was internally validated by bootstrap methods applied to
tree-based analysis [27]. Finally, the whole model building
procedure was validated by a comprehensive leave-one-
out cross validation (see Additional file 1: supplementary
statistical methods). All p values are based on two-tailed
tests.
Results
Patients characteristics
Patients characteristics are reported in Table 1. Treat-
ment was administered according to NCI-WG indica-
tions. Deaths occurred mostly in treated patients (83%).
Deaths among untreated patients aged beyond 70 years
accounted for 11% of all deaths. All patients characteris-
tics were balanced across age groups <55, 55-64, 65-4
and ≥ 75(chi-square tests), except for a greater propor-
tion of males in the <55 age group and a greater pro-
portion of high b2 M levels and deaths events in the
≥75 age group. Kaplan-Meyer plots of OS and TTT are
shown in Figure 1.
Univariate and multivariate analysis for OS and TTT
In univariate analysis for OS all clinical and biological
variables were significant, except for del11q (Table 2).
The effect of chemoimmunotherapy was small, without
statistical significance. The effect of period of diagnosis
was significant, with patients diagnosed 2000-2005 and
>2005 at increasing risk compared to patients diagnosed
before 2001. Based on these results, multivariate analyses
were adjusted for the year of diagnosis introduced in the
model as a three level stratification factor (<=2000, 2001-
2005, >2005). Age dependent variations of variables
effects were explored by including an age interaction
term either in continuous form or as a four-group (<55,
55-64, 65-74, ≥75) ordinal variable in multivariate mod-
els. No significant variations in hazard ratio (HR) values
were found (p > 0.05 for all interactions). The selection
of the variables entered in final model was internally vali-
dated by bootstrap .632+ method [24]. All the variables
introduced in the final model were selected in more than
50% of bootstrap samples (Table 3); prediction error in
this step of model building was 0.244. The final model
fitting was also validated by bootstrap .632+ method,
showing at this step a prediction error of 0.247. Leave-
one-out cross validation [24,26]. showed that neither b2
M nor gender, the least important variables, could be
safely removed from the model (Table 4). Univariate and
multivariate analyses of TTT, performed on the subset of
Binet A patients below 70 years of age, are shown in
Table 5.
Table 1 Patients characteristics (n = 620)
median age, years (range) 65 (21-92)
median ALC, x109/L (range) 14 (2-460)
median b2M, xULN (range) 1.06 (0.13-11.9)
LNR ≥3 25%
Rai stage
0 48%
I-II 44%
III-IV 8%
Binet stage
A 70%
B 22%
C 8%
Male sex 60%
CD38 expression >30% 27%
ZAP-70 expression >20% 41%
Unmutated IgVH 41%
del11q- 9%
del17p- 10%
Year of diagnosis
<=2000 29%
2001-2005 49%
>2005 22%
Treated 53%
median TTT, years 5.2
Chemotherapy 28%
Chemoimmunotherapy 15%
missing data 10%
Dead 20%
median OS, years 15
ALC, absolute lymphocyte count; LNR, number of lymph node involved
regions; ULN, upper limit of normal; b2 M, beta-2 microglobulin, OS, overall
survival; TTT, time to treatment. Complete data (n = 620) available for all
variables, except for therapy
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Figure 1 Overall survival (OS) and time to treatment (TTT) in
the whole cohort of 620 CLL patients.
Table 2 Univariate and multivariate Cox regression analysis for overall survival
univariate multivariate
initial model final model
HR p HR p HR p
age>65 years 2.99 <0.0001 3.53 <0.0001 3.43 <0.0001
male sex 1.86 0.0018 1.84 0.0030 1.80 0.0038
ALC>14 × 109/L 1.67 0.0062 1.34 0.17 -
b2M>1 × ULN 1.43 <0.0001 1.51 0.06 1.59 0.029
LNR ≥3 3.06 <0.0001 1.20 0.59 -
Binet stage <0.0001
A ref ref ref
B 3.20 2.19 0.0352 2.77 <0.0001
C 4.95 2.86 0.0028 3.68 <0.0001
Rai stage <0.0001
0 ref ND
I-II 1.66 ND
III-IV 5.08 ND
CD38>30% 1.73 0.0038 1.03 0.88 -
ZAP-70>20% 1.53 0.0204 1.04 0.83 -
Unmutated IGHV 2.46 <0.0001 2.04 0.0008 2.04 0.0003
del17p 3.44 <0.0001 2.14 0.0015 2.06 0.0022
del11q 1.39 0.248 ND
Year of diagnosis 0.0130 (in model as strata)* (in model as strata)*
<2001 ref
2001-2005 1.46
>2005 2.34
Therapy 0.106 ND
Chemotherapy ref
Immunochemotherapy 0.6
Final model obtained by stepwise backward elimination
HR: hazard ratio; ND: not done
Table 3 Prognostic score for overall survival with clinical
and biological risk factors and bootstrap validation
final
model1
variable
selection2
b HR p % final
score
Age>65 years 1.23 3.43 <0.0001 100 2
Binet B 1.02 2.77 <0.0001 92 2
Binet C 1.30 3.68 <0.0001 92 3
Gender (male) 0.59 1.80 0.0038 94 1
b2M >1 ×
ULN
0.46 1.59 0.0294 66 1
Del17p 0.72 2.06 0.0022 93 1
Unmutated
IGHV
0.71 2.04 0.0003 98 1
calendar year (in strata) - - 87 -
HR: hazard ratio; b: Cox regression coefficient; ULN, upper limit of normal
1 Final model adjusted for year of diagnosis
2 Percentage of selection in 620 leave-one-out bootstrap samples. Percentages
for del11, ZAP-70, CD38, LFN, ALC were respectively 28%, 21%, 15%, 24%,
46%
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Clinical-biological prognostic index
The 4-variable clinical model previously proposed by us
[8] was refitted in the present CLL cohort (see Additional
file 2: Table S1). The 4-variable clinical model had a
greater discriminatory power (c-index 0.72) than the
6-variable clinical model by Wierda et al. (c-index 0.62;
p = 1.3 × 10-7). According to the b regression coefficients,
a novel clinical-biological prognostic score was developed
by assigning 3 points for Binet C stage, 2 points/each for
Binet B stage and age > 65 years, 1 point/each for male
gender, high b2 M levels, presence of an unmutated
IGHV gene status or 17p deletion (Table 3). The score
point distribution is reported in Figure 2a. To this
distribution we applied a recursive partitioning method
[23], which yielded three prognostic groups, with score
0-1, 2-5 and 6-9. The Kaplan-Meier plots of the three
risk group partitioning of the prognostic score is shown
in Figure 2b, for comparison also the risk group partition
by Wierda PI [3] is shown in Figure 2c. In particular, 21%
of patients (score 0-1) were at low-risk, 63% (score 2-5)
were at intermediate risk, and 16% of patients (score 6-9)
were at high risk. Projected survival in respectively low,
intermediate and high-risk groups was 98%, 90%, 58%,
and 98%, 69% 9% at 5-year and10-year, respectively. Pre-
dictive accuracies were significantly greater in the clini-
cal-biological model, compared to the 6-variable clinical
model by Wierda et al. (c-index 0.73 vs 0.62, p < 0.0001)
[3], or to the 4-variable clinical model (c-index 0.73 vs
0.72, p < 0.0001) [8], or to Binet (c-index 0.73 vs 0.65, p <
0.0001), or Rai (0.73 vs 0.62, p < 0.0001) staging systems.
To show the combination of predictive variables in each
patients and in each group we used a heat-map plot
(Figure 3). In the low risk group, comprising 133 cases,
52 patients had no adverse predictors (score 0), 50
patients were male, 16 patients had a b2 M > 1 and 15
patients had unmutated IGHV gene mutational status.
Of note, low risk patients were never aged >65, nor had a
Binet staging B or C, or were affected by a CLL bearing
del17p (Figure 4). Conversely, in the high-risk group,
only 3 or 4 patients, respectively, had <65 years or a
Binet stage A disease; these patients, however, had all the
other prognosticators in their bad configuration. More-
over, the 51 patients in Binet stage B of the high-risk
group, had mostly (37/51) an unmutated IGHV gene sta-
tus or high b2 M (42/51) levels. Finally, the 29 patients
classified in Binet stage C and belonging to the high-risk
group, mostly had (26/29) high b2 M levels (Figure 4).
Kaplan-Meyer plots of the individual variables are
reported in Figure 4.
Nomogram for estimating prognosis in individual
patients
Even if individual estimates of survival, as those obtained
from nomograms, are more likely affected by inaccuracy
than group estimates [28], to allow individual patients sur-
vival estimation a nomogram was developed as described
previously [8], based on the final model with clinical and
biological prognostic factors shown in Table 3, modified
using age and b2 M as continuous variables (Figure 5).
The clinical-biological nomogram showed a better predic-
tive accuracy than the clinical nomogram proposed
by Wierda et al. [3] (c-index respectively 0.79 and 0.76,
p = 0.046).
Discussion
Survival time at CLL diagnosis may be simply estimated by
means of six variables, four of them clinical-demographic
Table 4 Leave-one-out cross validation of the final model
Step covariate removed no. of variables log-l AIC cvlog-l
0 all (null model) 0 -675.7 -675.7 -846.8
1 none (final model) 6 -502.1 -509.1 -743.1
2 b2M 5 -504.6 -510.6 -738.8
3 b2M and sex 4 -618.9 -623.9 -738.8
The final model included the following 6 variables: Binet stage, age > 65
years, unmutated IgVH, presence of del17p, male sex, b2 M > ULN
Log-l: log-likelihood, AIC: Akaike’s information criterion (AIC); cvlog-l: cross-
validated log likelihood Removal of the least important variables (beta2M and
sex) in step 2 and 3 resulted in a reduction of the fit by at least 2 criteria,
demonstrating the validity of the model with 6 variables (according to
reference #26)
Table 5 Univariate and multivariate analysis of TTT in
Binet A patients below 70 year of age (n = 291, no
missing cases)
univariate multivariate
initial
model
final model
% HR p HR p HR p
age>65 years 22 0.96 0.85 -
male sex 56 1.01 0.97 -
ALC>14 ×
109/L
42 1.35 0.0974 -
b2M>1 × ULN 38 2.04 <0.0001 1.53 0.0242 1.64 0.0069
CD38>30% 21 2.46 <0.0001 1.42 0.1042 -
ZAP-70>20% 36 2.72 <0.0001 1.39 0.1374 -
Unmutated
IGHV
32 3.60 <0.0001 2.16 0.0012 3.09 <0.0001
del17p 7 2.59 0.0015 1.37 0.31 -
del11q 5 3.09 0.0005 2.21 0.02 1.97 0.0383
Year of
diagnosis
0.85 -
<2001 33 ref
2001-
2005
48 1.07
>2005 19 0.89
Final model obtained by stepwise backward elimination
HR: hazard ratio
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(stage, LNR, sex, age) plus two quantitative assays (ALC,
b2 M) [3,4,8]. Two independent studies [4,8] failed to con-
firm the predictive power of ALC. A simplification of the
PI from six to four variables was previously proposed by
us as capable to stratify patients with equal or better per-
formance [8]. In the present study, the aim was to improve
these clinical prognostic models by adding information on
biological variables, in particular those identified by the
updated NCI-WG guidelines [1] as mandatory at least in
the context of clinical trials. We demonstrated that PI for
OS prediction based on clinical variables could be
improved only by IGHV gene mutational status and
del17p, but not CD38, ZAP-70 and del11q. The lack of
prognostic power of CD38 and ZAP-70 is not totally
unexpected. Similar findings have been found either ana-
lyzing OS [13,14,29] or TTT [30,31], although none of
these reports included both biological and clinical prog-
nosticators in a comprehensive clinical-biological PI, as
proposed here. It has been often emphasized that assays
evaluating ZAP-70 and, at least in part, CD38 expression
suffer from inherent weakness and lack of proper standar-
dization [13,32-34]. As a consequence, considerable analy-
tic variability still exists on measurement of these
parameters [35]. In this regard, such a variability could be
more relevant in multi-center series like that investigated
in this study. Indeed, at variance with our results, ZAP-70
or CD38 turned out to be among the strongest prognosti-
cators in mono-center studies [36,37], with time-to-first-
treatment or time-to-progression as end-points. Lack of
reproducibility and standardization of biological markers
can affect the results of prognostic tools applied at differ-
ent institutions. Our model might be less subjected to this
bias, since it includes IGHV and del17p, but not the less
standardized measurements of CD38 and ZAP-70. Krober
et al. [13,14] have previously showed the importance of
molecular risk factors in CLL by stratifying patients by
IGHV gene mutational status and presence of high-risk
genomic aberrations (del17p or del11q), although authors
failed to test if their model was independent of clinical and
demographic risk factors. Here we had the chance to inte-
grate the data by Krober et al. [13,14] by showing the inde-
pendent prognostic relevance of UM IGHV gene status
and del17p in a model that also included clinical and
demographic risk factors. Of note, the effect of these mole-
cular prognosticators was found to be additive and of
equal importance. The unexpected limited relevance of
molecular risk factors in our model and the lacking pre-
dictive power of CD38 and ZAP-70, may be in part justi-
fied by a relative small number or deaths and a median
follow up of only 5 years, despite the large number of
patients collected. Future analyses with longer follow-up
data and more events might regain significance to some
clinical−biological score
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Figure 2 Clinical-biological index. a) histogram of score points
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biological variables showing the need to update the score.
Compared to our previous clinical model [8], we con-
firmed the value of b2 M, although with the smallest coef-
ficient and the weakest level of significance. We had no
data to adjust for renal function impairment, particularly
in aged patients, or for other comorbidities. However, b2
M was shown to be important in other retrospective and
prospective studies [38-40]. The value of prognostic fac-
tors in aged CLL patients has been recently criticized by
showing that FISH aberrations (del11q or del 17q) and
IGVH lost their predictive power for OS in patients aged
above 75 years [41]. In our CLL series, we specifically
addressed this issue by testing age dependent variations of
the predictive power of all the variables included in the
final model. No significant interaction effect was found for
age. We found a greater proportion of death events in the
oldest age group. The risk of death in this group may be
influenced by other factors, not related to disease. How-
ever, epidemiological data from cancer registry show the
frequent occurrence of late deaths attributable to CLL also
in aged patients group [42,43]. The effect of chemoimmu-
notherapy with anti-CD20 was small, with a non signifi-
cant trend for a longer survival (p = 0.10). Results of the
present study differed in part from those of a randomized
prospective trial [40], where Binet stage and gender, in
addition to del11q, CD38 and ZAP-70, all failed to be
independent prognostic markers in a multivariate model
for OS which also included IGHV gene mutational status,
52 81 100 121 101 65 49 37 13
0 1 2 3 4 5 6 7 8
age>65 years
Binet
male sex
β2M>ULN
del 17p
UM−IGVH
no. of patients
score
risk group
133 387 100
low intermediate high
9
1
Figure 3 Heatmap of individual patient clinical-biological scores. Columns refer to individual patient; rows refer to predictors. In heatmap,
each dicotomic predictor is indicated in green or red if present in its favourable or unfavourable configuration, respectively. Binet stages A, B, C
are indicated in green, red and black, respectively. Yellow bars show the splits between low, intermediate and high-risk groups. Number of
patients in each score class are reported at the bottom of columns.
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usage of IGHV3-21 gene, del17p, age and b2 M. Notably,
this study, which investigated a population of selected
patients in need of treatment (i.e. with active or progres-
sive disease), selected del17p as the strongest risk factor
[40]. Conversely, in our retrospective study dealing with
untreated patients at diagnosis, the relative weight of
del17p appeared equal or lower than that of other vari-
ables. Therefore, while the model described in [40] seems
to better predict outcome of CLL patients with progressive
or active disease, our model appears to be more suited for
estimating survival in untreated patients at diagnosis or
before clinical progression. The analysis of TTT in Binet
A patients below 70 years of age showed that demographic
factors (age, gender), important for OS estimation, lost
their prognostic power for TTT. Conversely, It might be
expected that biological prognosticator, particularly those
with limited or even absent significance in the OS
analyses, would have gained more importance in the TTT
analyses in this subset of patients. However only IGHV
and b2 M confirmed their role, with IGHV the most
important predictor of TTT. CD38 and ZAP-70 were
again not significant, in spite of a good representation of
positive cases (respectively 21% and 36%); del17p lost its
power whereas del11q gained significance. In this case the
low percentage of positive cases may, at least in part, jus-
tify the fluctuating results.
Conclusions
In the present study we showed that the survival of
untreated CLL patients may be estimated by a limited
set of clinical and biological variables, integrated in a
prognostic index and in a nomogram, allowing group
and individual estimation, respectively. CD38, ZAP-70
and del11q gave redundant prognostic information.
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Both the proposed PI and the nomogram were only
internally validated. Even in internally validated models,
the performance of prognostic tools may be influenced
or biased by the composition of the population in which
they are developed and lack of standardization of biolo-
gical variables. Therefore the prognostic tools proposed
should be used with caution until externally validated
on independent, prospective patient series.
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Figure 5 Kaplan-Meyer plots of overall survival (OS) for the 6 variable of the clinical-prognostic index.
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Additional material
Additional file 1: Supplementary statistical methods. Details of
validation procedures for the whole prognostic model.
Additional file 2: Table S1. Previously proposed prognostic score for
overall survival with clinical risk factors.
Abbreviations
ALC: absolute lymphocyte count; β2M: beta2-microglobulin; FISH:
fluorescence in-situ hybridization; LNR: number of involved lymph node
regions; HR: hazard ratio; IGHV: immunoglobulin heavy chain variable gene
segments; OS: overall survival; PI: prognostic index; TTT: time to treatment;
ULN: upper limit of normal.
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